Abstract
We report a case of CA19-9 producing transitional cell carcinoma of the right ureter effectively responsive to combination chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) regimen) in a 53-year-old woman. The maximum level of serum CA19-9 showed 3,000 U/ml and clinical staging of the tumor was T4 N3 M0. Marked regression of the tumor was identified by computed tomographic scan and the level of serum CA19-9 returned to the normal range after 3 courses of M-VAC therapy. Right total nephro-ureterectomy and partial cystectomy was done and the surgical specimen revealed no viable tumors. She is alive without evidence of local recurrence or metastasis at 6 months after resection. The serum CA19-9 level was useful for monitoring the clinical course.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Antigens, Tumor-Associated, Carbohydrate / biosynthesis*
-
Antigens, Tumor-Associated, Carbohydrate / blood
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / blood*
-
Carcinoma, Transitional Cell / diagnosis
-
Carcinoma, Transitional Cell / drug therapy*
-
Chemotherapy, Adjuvant
-
Cisplatin / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Methotrexate / administration & dosage
-
Middle Aged
-
Tomography, X-Ray Computed
-
Ureter / surgery
-
Ureteral Neoplasms / diagnosis
-
Ureteral Neoplasms / drug therapy*
-
Vinblastine / administration & dosage
Substances
-
Antigens, Tumor-Associated, Carbohydrate
-
Biomarkers, Tumor
-
Vinblastine
-
Doxorubicin
-
Cisplatin
-
Methotrexate